(Q37850188)

English

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

scientific article published on 04 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 August 2017

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

24 August 2017

phase III clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Jean-Pascal Machiels

1

1 reference

Europe PubMed Central

24 August 2017

Somasundaram Subramanian

2

1 reference

Europe PubMed Central

24 August 2017

Agnes Ruzsa

3

1 reference

Europe PubMed Central

24 August 2017

Gabor Repassy

4

1 reference

Europe PubMed Central

24 August 2017

Igor Lifirenko

5

1 reference

Europe PubMed Central

24 August 2017

Annika Flygare

6

1 reference

Europe PubMed Central

24 August 2017

Tina Nielsen

8

1 reference

Europe PubMed Central

24 August 2017

Steen Lisby

9

1 reference

Europe PubMed Central

24 August 2017

Paul M J Clement

10

1 reference

Europe PubMed Central

24 August 2017

Per Sørensen

7

1 reference

Europe PubMed Central

24 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 March 2011

1 reference

Europe PubMed Central

24 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

24 August 2017

12

1 reference

Europe PubMed Central

24 August 2017

333-343

1 reference

Europe PubMed Central

24 August 2017

4

1 reference

Europe PubMed Central

24 August 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970034-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70034-1

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37850188&oldid=1730889979"